Aptinyx Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress
21 mars 2019 07h07 HE
|
Aptinyx Inc.
Completed Phase 2 study of NYX-2925 in painful DPN -- did not meet primary endpoint, but NYX-2925 demonstrated robust analgesic activity in a large and mechanistically relevant patient sub-group ...
Aptinyx to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 21, 2019
14 mars 2019 08h00 HE
|
Aptinyx Inc.
EVANSTON, Ill., March 14, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx to Present at Cowen and Company 39th Annual Health Care Conference
06 mars 2019 08h00 HE
|
Aptinyx Inc.
EVANSTON, Ill., March 06, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx to Present at 8th Annual SVB Leerink Global Healthcare Conference
22 févr. 2019 08h00 HE
|
Aptinyx Inc.
EVANSTON, Ill., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx Initiates Phase 2 Study to Evaluate Safety and Efficacy of NYX-783 in Patients with Post-Traumatic Stress Disorder
19 févr. 2019 07h27 HE
|
Aptinyx Inc.
Favorable safety and tolerability, linear pharmacokinetics, and ample CNS exposure of NYX-783 observed in Phase 1 Phase 2 data anticipated 1H 2020 EVANSTON, Ill., Feb. 19, 2019 (GLOBE NEWSWIRE) --...
Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
16 janv. 2019 07h27 HE
|
Aptinyx Inc.
NYX-2925 did not achieve statistically significant separation from placebo on primary endpoint Meaningful improvements on pain and other endpoints observed in subjects receiving 50 mg dose and in...
Aptinyx to Present at 37th Annual J.P. Morgan Healthcare Conference
02 janv. 2019 08h07 HE
|
Aptinyx Inc.
EVANSTON, Ill., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx to Present Preclinical Data on NMDA Receptor Modulator NYX-2925 at the American College of Neuropsychopharmacology’s Annual Meeting
11 déc. 2018 08h27 HE
|
Aptinyx Inc.
EVANSTON, Ill., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
05 déc. 2018 08h07 HE
|
Aptinyx Inc.
EVANSTON, Ill., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia
03 déc. 2018 07h27 HE
|
Aptinyx Inc.
Achieved statistical significance on primary imaging-based endpoint, changes in markers of central pain processing, in 11 subjects Observed corresponding trends of improvement on multiple secondary...